Hengrui medicine: a number of drugs have been approved to carry out clinical trials

Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows

A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?

Chinese tech giant Huawei and Vietnam’s SHB Bank enter strategic partnership to accelerate penetration into SE Asia's financial cloud market

On April 22, Saigon-Hanoi Commercial Joint Stock Bank (SHB) of Vietnam officially announced the signing of a strategic cooperation agreement with Chinese tech giant Huawei. Under the agreement, Huawei will be deeply involved in SHB’s technical architecture design, assisting in the construction of its core data platform and providing comprehensive operational stability and security assurance.

Beijing Pilots The DRG External Payment Mode

DRG refers to the diagnosis-related group used to classify the patient and set up a system to ensure the care provided is necessary. The National Healthcare Security Administration will pay the hospital a predetermined amount according to a patient’s DRG.

CSPC Pharma’s Arthritis Painkiller Listed by China's Medical Agency

CSPC Pharmaceutical has seized the chance of entry into the third national centralized procurement and expects stable sales for the generic drug Celecoxib.

New Normal, New Policies: A Focus on Healthcare in Two Sessions 

The week-long Chinese virtual ‘Two Sessions’ meeting closed on May 28. The hovering pandemic has made the healthcare topic a highlight for the 2020 third session of the 13th National People’s Congress.